^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

Talvey (talquetamab-tgvs)

i
Other names: JNJ 7564, JNJ-64407564, JNJ 64407564, JNJ-7564 , JNJ64407564, JNJ7564
Company:
J&J
Drug class:
CD3 agonist, GPRC5D inhibitor
Related drugs:
16d
Clearance of Circulating Multiple Myeloma Cells to Assess Early Response to Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma (ASH 2024)
Currently, two BCMA-targeting BsAbs (teclistamab and elranatamab) and one GPRC5D-targeting BsAb (talquetamab) have regulatory approval for the treatment of patients (pts) with RRMM. CMMC counts through serial peripheral blood sampling can be used to assess disease burden and early kinetics of response to BsAb therapy. Further follow-up and additional cohorts are planned to confirm performance of this assay as a biomarker in predicting response and long-term outcomes in patients receiving BsAb and other therapies, as well as interrogating mechanisms of resistance through targeted sequencing and analysis of tumor-associated antigens of enumerated cells.
IO biomarker
|
PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • SDC1 (Syndecan 1)
|
CELLSEARCH®
|
Elrexfio (elranatamab-bcmm) • Talvey (talquetamab-tgvs) • Tecvayli (teclistamab-cqyv)
16d
Pharmacodynamic Signatures and Correlatives of Response in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Talquetamab or Teclistamab Plus Daratumumab and Pomalidomide (ASH 2024)
Tal-DP exhibits a deep, long-term impact on efficacy through complementary mechanisms of action and may be especially beneficial in pts with prior BsAb exposure, who typically have unfavorable BL immune profiles. Ongoing analyses of tec-DP from MajesTEC-2 (NCT04722146) will be presented.
Clinical • PK/PD data • PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • LAG3 (Lymphocyte Activating 3) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2)
|
CD38 expression • CD8 expression • LAG3 expression
|
Darzalex (daratumumab) • pomalidomide • Talvey (talquetamab-tgvs) • Tecvayli (teclistamab-cqyv)
21d
Trial primary completion date
|
pomalidomide • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • Talvey (talquetamab-tgvs) • Tecvayli (teclistamab-cqyv)
30d
GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5 (clinicaltrials.gov)
P2, N=130, Recruiting, University of Heidelberg Medical Center | N=70 --> 130 | Trial completion date: Oct 2027 --> Aug 2028 | Trial primary completion date: Oct 2026 --> Feb 2027
Enrollment change • Trial completion date • Trial primary completion date
|
lenalidomide • bortezomib • dexamethasone • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • Talvey (talquetamab-tgvs) • Tecvayli (teclistamab-cqyv)
1m
Talisman: A Study to Evaluate Preventive Treatments for Talquetamab-related Oral Toxicity (clinicaltrials.gov)
P2, N=120, Active, not recruiting, Janssen Research & Development, LLC | Recruiting --> Active, not recruiting
Enrollment closed
|
Talvey (talquetamab-tgvs)
1m
MonumenTAL-8: A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma (clinicaltrials.gov)
P2, N=30, Recruiting, Janssen Research & Development, LLC | Trial completion date: Apr 2028 --> Feb 2027
Trial completion date
|
lenalidomide • Darzalex (daratumumab) • dexamethasone • Carvykti (ciltacabtagene autoleucel) • Talvey (talquetamab-tgvs)
1m
Trial primary completion date • Combination therapy • Checkpoint inhibition
|
Talvey (talquetamab-tgvs) • Tecvayli (teclistamab-cqyv)
2ms
Talisman: A Study to Evaluate Preventive Treatments for Talquetamab-related Oral Toxicity (clinicaltrials.gov)
P2, N=120, Recruiting, Janssen Research & Development, LLC | Not yet recruiting --> Recruiting
Enrollment open
|
Talvey (talquetamab-tgvs)
2ms
Talquetamab & Lenalidomide as Post Stem Cell Transplant Maintenance in Multiple Myeloma (clinicaltrials.gov)
P2, N=30, Not yet recruiting, Stanford University | Initiation date: Jul 2024 --> Nov 2024
Trial initiation date
|
lenalidomide • Talvey (talquetamab-tgvs)
2ms
Enrollment open
|
lenalidomide • Darzalex (daratumumab) • dexamethasone • Carvykti (ciltacabtagene autoleucel) • Talvey (talquetamab-tgvs)
2ms
Evaluation of Drug-Drug Interaction Potential of Talquetamab, a T-Cell-Redirecting GPRC5D × CD3 Bispecific Antibody, as a Result of Cytokine Release Syndrome in Patients with Relapsed/Refractory Multiple Myeloma in MonumenTAL-1, Using a Physiologically Based Pharmacokinetic Model. (PubMed, Target Oncol)
These modeling results suggest that IL-6 release due to talquetamab-induced cytokine release syndrome has limited impact on potential drug-drug interactions, with the highest likelihood of impact occurring from initiation of talquetamab step-up dosing up to 7 (QW) or 9 (Q2W) days after first treatment dose in cycle 1 and during and after cytokine release syndrome. Multiple myeloma can be treated with immunotherapies such as the bispecific antibody, talquetamab, which binds the novel antigen G protein-coupled receptor family C group 5 member D on multiple myeloma cells and CD3 on T cells and induces T-cell-mediated lysis of multiple myeloma cells. Following talquetamab treatment, many patients experience cytokine release syndrome, an inflammatory immune response where levels of proinflammatory cytokines, including interleukin (IL)-6, are increased. Interleukin-6 can suppress the activity of important enzymes in the body (cytochrome [CYP] P450s) that are involved in drug clearance. This study used a physiologically based pharmacokinetic computer model to investigate the potential impact of increased IL-6 levels on CYP450 enzymes to determine subsequent impact on drugs that are metabolized by CYP450 enzymes. The results showed no predicted interaction between median levels of IL-6 observed in patients and CYP substrates (such as caffeine and omeprazole) with talquetamab. In a simulation that assessed higher (maximum) IL-6 levels observed in patients, the predicted impact of IL-6 was minimal to weak for most of the CYP substrates assessed. The effect on CYP450 enzymatic activity was highest from initiation of talquetamab step-up dosing up to 7-9 days after the first treatment dose of talquetamab. These results suggest that, in this treatment time period, elevated IL-6 levels due to talquetamab-induced cytokine release syndrome have limited impact on drugs that are CYP substrates that may be used in conjunction with talquetamab, but that the concentration and toxicity of these drugs should be monitored and the dose of CYP substrate adjusted as required.
PK/PD data • Journal
|
IL6 (Interleukin 6) • CYP1A2 (Cytochrome P450, family 1, subfamily A, polypeptide 2) • CYP2C9 (Cytochrome P450 Family 2 Subfamily C Member 9) • CYP3A4 (Cytochrome P450, family 3, subfamily A, polypeptide 4) • CYP3A5 (Cytochrome P450 Family 3 Subfamily A Member 5)
|
IL6 elevation
|
Talvey (talquetamab-tgvs) • omeprazole
3ms
New P2 trial
|
lenalidomide • bortezomib • cyclophosphamide • fludarabine IV • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • Carvykti (ciltacabtagene autoleucel) • Talvey (talquetamab-tgvs) • Tecvayli (teclistamab-cqyv)
3ms
New P1/2 trial • Combination therapy
|
Talvey (talquetamab-tgvs)
3ms
Nursing Considerations for the Clinical Management of Adverse Events Associated with Talquetamab in Patients with Relapsed or Refractory Multiple Myeloma. (PubMed, Semin Oncol Nurs)
Oncology nurses have specialized knowledge of treatment administration monitoring based on their participation in the MonumenTAL-1 trial. This review provides information for nurses in both the academic and community settings on how to monitor, counsel, and support patients, which will in turn improve patients' quality of life and overall survival.
Review • Journal • Adverse events
|
GPRC5D (G Protein-Coupled Receptor Class C Group 5 Member D)
|
Talvey (talquetamab-tgvs)
3ms
OPTec: Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma (clinicaltrials.gov)
P2, N=75, Recruiting, SCRI Development Innovations, LLC | N=50 --> 75
Enrollment change
|
Actemra IV (tocilizumab) • Talvey (talquetamab-tgvs) • Tecvayli (teclistamab-cqyv)
3ms
MonumenTAL-2: A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma (clinicaltrials.gov)
P1, N=167, Active, not recruiting, Janssen Research & Development, LLC | Recruiting --> Active, not recruiting
Enrollment closed
|
carfilzomib • pomalidomide • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • Talvey (talquetamab-tgvs)
3ms
Enrollment closed • Enrollment change • Combination therapy • Checkpoint inhibition
|
Talvey (talquetamab-tgvs) • Tecvayli (teclistamab-cqyv)
3ms
A Study of JNJ-64407564 in Japanese Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
P1, N=15, Active, not recruiting, Janssen Pharmaceutical K.K. | Trial completion date: Aug 2024 --> Aug 2025
Trial completion date
|
Talvey (talquetamab-tgvs)
3ms
New P2 trial
|
lenalidomide • Darzalex (daratumumab) • dexamethasone • Carvykti (ciltacabtagene autoleucel) • Talvey (talquetamab-tgvs)
4ms
Trial completion date • Combination therapy • Checkpoint inhibition
|
Talvey (talquetamab-tgvs) • Tecvayli (teclistamab-cqyv)
4ms
New P2 trial
|
lenalidomide • bortezomib • Darzalex (daratumumab) • dexamethasone • Talvey (talquetamab-tgvs) • Tecvayli (teclistamab-cqyv)
4ms
New P2 trial
|
Talvey (talquetamab-tgvs)
5ms
Enrollment change • Trial completion date
|
Talvey (talquetamab-tgvs) • Tecvayli (teclistamab-cqyv)
5ms
New P2 trial
|
lenalidomide • Talvey (talquetamab-tgvs)
6ms
Trial primary completion date
|
Talvey (talquetamab-tgvs) • Tecvayli (teclistamab-cqyv)
7ms
T cell characteristics impact response and resistance to T cell-redirecting bispecific antibodies in multiple myeloma. (PubMed, Clin Cancer Res)
Primary resistance is characterized by a low T-cell/MM cell-ratio and Treg-driven immunosuppression, while reduced T-cell fitness due to continuous BsAb-mediated T-cell activation may contribute to development of acquired resistance.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-1 (Programmed cell death 1) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • CD4 (CD4 Molecule)
|
Talvey (talquetamab-tgvs) • Tecvayli (teclistamab-cqyv)
7ms
Trial primary completion date • Combination therapy
|
lenalidomide • bortezomib • pomalidomide • Empliciti (elotuzumab) • Talvey (talquetamab-tgvs) • Tecvayli (teclistamab-cqyv) • dexamethasone injection
7ms
TALMMY1001-PT3: A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
P2, N=450, Recruiting, Janssen Research & Development, LLC | Trial completion date: Apr 2026 --> Dec 2026
Trial completion date
|
Talvey (talquetamab-tgvs)
8ms
New P2 trial • Minimal residual disease
|
lenalidomide • bortezomib • Darzalex (daratumumab) • dexamethasone • Talvey (talquetamab-tgvs) • Tecvayli (teclistamab-cqyv)
8ms
New P1 trial
|
Talvey (talquetamab-tgvs) • iberdomide (CC-220) • Hemady (dexamethasone tablets)
8ms
Trial primary completion date • Combination therapy
|
lenalidomide • dexamethasone • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • Talvey (talquetamab-tgvs) • Tecvayli (teclistamab-cqyv)
8ms
Trial completion date • Combination therapy
|
pomalidomide • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • Talvey (talquetamab-tgvs) • Tecvayli (teclistamab-cqyv)
9ms
MonumenTAL-2: A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma (clinicaltrials.gov)
P1, N=182, Recruiting, Janssen Research & Development, LLC | Trial primary completion date: Dec 2024 --> Jul 2025
Trial primary completion date
|
carfilzomib • pomalidomide • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • Talvey (talquetamab-tgvs)
9ms
A Study of JNJ-64407564 in Japanese Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
P1, N=15, Active, not recruiting, Janssen Pharmaceutical K.K. | Trial completion date: Dec 2024 --> Aug 2024
Trial completion date
|
Talvey (talquetamab-tgvs)
9ms
Trial primary completion date
|
lenalidomide • Abecma (idecabtagene vicleucel) • Talvey (talquetamab-tgvs)
10ms
Enrollment open
|
lenalidomide • bortezomib • pomalidomide • Empliciti (elotuzumab) • Talvey (talquetamab-tgvs) • Tecvayli (teclistamab-cqyv) • dexamethasone injection
10ms
New P3 trial • Combination therapy
|
lenalidomide • bortezomib • pomalidomide • Empliciti (elotuzumab) • Talvey (talquetamab-tgvs) • Tecvayli (teclistamab-cqyv) • dexamethasone injection
11ms
Enrollment change
|
Talvey (talquetamab-tgvs)
12ms
Phase classification • Combination therapy • Checkpoint inhibition
|
Talvey (talquetamab-tgvs) • Tecvayli (teclistamab-cqyv)
12ms
A Study of JNJ-64407564 in Japanese Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
P1, N=15, Active, not recruiting, Janssen Pharmaceutical K.K. | Recruiting --> Active, not recruiting
Enrollment closed
|
Talvey (talquetamab-tgvs)
12ms
MonumenTAL-2: A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma (clinicaltrials.gov)
P1, N=182, Recruiting, Janssen Research & Development, LLC | Phase classification: P1b --> P1
Phase classification
|
carfilzomib • pomalidomide • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • Talvey (talquetamab-tgvs)
12ms
Phase classification • Combination therapy
|
pomalidomide • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • Talvey (talquetamab-tgvs) • Tecvayli (teclistamab-cqyv)